Daniel Wiegand is a synthetic biologist, chemical engineer, and entrepreneur. During his nearly decade-long tenure (2013-2022) as a member of the Advanced Technology Team at the Wyss Institute for Biologically Inspired Engineering at Harvard University, he worked on array-based oligonucleotide synthesis, nucleic acid-based data storage, engineering novel RNA polymerases, and next-generation sequencing chemistries. He went on to co-found EnPlusOne Biosciences in 2022, serving as its inaugural CEO, raising $12M in seed financing, and leading development of its enzymatic oligonucleotide synthesis platform for scaled manufacturing of RNA therapeutics. Daniel is an alumnus of the Nucleate program (cohort 2020) and holds a B.S. in Biochemistry and M.S. in Chemical Engineering from Northeastern University.

Sauveur has over a decade of research experience in cell biology, tissue engineering, organoids, and organ-on-a-chip technology. The formative years of his career were spent at the Wyss Institute at Harvard University, where he made significant contributions to foundational research on the Kidney-Chip, iPSC reprogramming, and iPSC-derived renal lineages, co-authoring several high-impact papers, including a chapter in the book “Innovation in Nephrology.” Subsequently, he joined Emulate, where he advanced from Senior Scientist to Principal Scientist over nearly six years. During his tenure, he drove the commercial launch of the Proximal Tubule Kidney-Chip and led complex in vitro studies across various organ chip platforms, including kidney, liver, lung, and brain, for pharmaceutical and biotech clients. Sauveur earned his B.S. in Biology and Economics at Northeastern University, where he is also currently working toward completing a M.S. in Bioengineering.

Bio Forthcoming

Richie Kohman is an inventor, scientist, and research institute executive with over 15 years of experience building and leading high-risk, high-reward research programs across academic, industrial, and nonprofit settings. As Lead of the Synthetic Biology Platform at Harvard's Wyss Institute for Biologically Inspired Engineering, he worked alongside Dr. George Church to advance programs spanning nucleic acid synthesis, next-generation sequencing, gene editing, and genome engineering. He subsequently served as Chief Scientific Officer of the Wyss Center for Bio and Neuroengineering in Geneva, overseeing a broad portfolio of translational neurotechnology and synthetic biology programs. He also served as co-PI of the IARPA MICrONS project, one of the largest efforts to map synaptic connectivity in the brain. Richie holds a Ph.D. in Organic Chemistry from the University of Illinois Urbana-Champaign.

George Church is the Robert Winthrop Professor of Genetics at Harvard Medical School, Professor of Health Sciences and Technology at Harvard and MIT, and a founding member of the Wyss Institute for Biologically Inspired Engineering. Widely regarded as a founder of modern genomics, he developed the first direct genome sequencing method, co-initiated the Human Genome Project, and launched the Personal Genome Project. At the Wyss Institute, he directs the Synthetic Biology Platform, where his lab has pioneered enzymatic nucleic acid synthesis, genome engineering, and novel biopolymers. His innovations form foundational pillars of the synthetic biology field, and his laboratory has catalyzed the founding of more than 50 biotechnology companies spanning gene therapy, RNA therapeutics, genome sequencing, and synthetic biology. He is elected to the National Academies of Sciences and Engineering and has co-authored 782 papers and 170 patent publications, including the book Regenesis.